Last reviewed · How we verify
BTV100 Mid dose
BTV100 is a monoclonal antibody targeting CD19.
BTV100 is a monoclonal antibody targeting CD19. Used for Relapsed or refractory diffuse large B-cell lymphoma, Relapsed or refractory follicular lymphoma.
At a glance
| Generic name | BTV100 Mid dose |
|---|---|
| Sponsor | BioTheraVision, Inc. |
| Drug class | CD19-targeting monoclonal antibody |
| Target | CD19 |
| Modality | Small molecule |
| Therapeutic area | Oncology |
| Phase | Phase 2 |
Mechanism of action
BTV100 works by binding to CD19 on the surface of B cells, marking them for destruction by the immune system. This leads to a reduction in B cell counts and a decrease in disease activity. BTV100 is designed to be a targeted therapy for B cell malignancies.
Approved indications
- Relapsed or refractory diffuse large B-cell lymphoma
- Relapsed or refractory follicular lymphoma
Common side effects
- Neutropenia
- Thrombocytopenia
- Anemia
Key clinical trials
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |